83112-50-9

Usage

Uses

Used in Pharmaceutical Industry:
α-hydroxy-3-cyanoacetophenone is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique chemical reactivity and functional groups make it an essential component in the development of new drugs.
Used in Agrochemical Industry:
α-hydroxy-3-cyanoacetophenone is used as a key intermediate in the preparation of agrochemicals. Its functional groups contribute to the creation of effective compounds for agricultural applications.
Used in Fine Chemicals Industry:
α-hydroxy-3-cyanoacetophenone is used as a key intermediate in the synthesis of fine chemicals. Its versatility allows for the production of a wide range of specialty chemicals.
Used in Material Science:
α-hydroxy-3-cyanoacetophenone is used in the development of new materials, such as liquid crystals and photochromic compounds. Its unique properties contribute to the advancement of these innovative materials.
Used in Medicinal Chemistry Research:
α-hydroxy-3-cyanoacetophenone is used as an interesting target for medicinal chemistry research due to its potential biological activities. Its unique structure and functional groups make it a promising candidate for the discovery of new therapeutic agents.

Upstream product

• 6136-68-1 3-acethylbenzonitrile 
• 83112-49-6 α-acetoxy-3-cyanoacetophenone 
• 69113-59-3 3-iodobenzonitrile 
• 50916-55-7 3-(2-bromoacetyl)benzonitrile 

Downstream Products

• 1215086-02-4 3-[2-(2-propenyloxy)acetyl]benzonitrile 
• 1002750-37-9 3-(2-{tert-butyldimethylsilyloxy}acetyl)benzonitrile 
• 212374-06-6 R-3-(1,2-dihydroxyethyl)benzonitrile 
• 212374-02-2 3-(1,2-dihydroxyethyl)benzonitrile 
• 50-00-0 formaldehyd 
• 1877-72-1 3-Cyanobenzoic acid 

Relevant academic research and scientific papers

Synthesis of α-hydroxyacetophenones

A general method for the preparation of α-hydroxyacetophenones is presented. Functionalized arylmagnesium species are transmetalated to the corresponding arylzinc intermediates, which undergo Cu(I)-catalyzed reaction with acetoxyacetyl chloride. Acidic hy

Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator

Structural modification performed on a 4-methyl-4-(4-hydroxyphenyl) hydantoin series is described which resulted in the development of a new series of 4-(hydroxymethyl)diarylhydantoin analogues as potent, partial agonists of the human androgen receptor. T

NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Novel compounds are disclosed that have a Formula represented by the following: wherein X, R1, R2a, R2b, R2c, R3a R3b, R4a, R4b, R4c, and ml are as describe

OXIME COMPOUNDS AND THE USE THEREOF

The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CRsu

Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)

Inhibitors of poly(ADP-ribose)polymerase (PARP) inhibit repair of damaged DNA and thus potentiate radiotherapy and chemotherapy of cancer. 3-Substituted benzamides and 5-substituted isoquinolin-1-ones have been synthesised and evaluated for inhibition of PARP. Reduction of 3-(bromoacetyl)benzamide, followed by treatment with base, gave RS-3-oxiranylbenzamide. Reduction of 3-(hydroxyacetyl)benzonitrile with bakers' yeast gave the R-diol which was converted to R-3-(1,2-dihydroxyethyl)benzamide. Similar reduction of 3-(acetoxyacetyl)benzonitrile led towards the S-diol which was converted to its cyclic acetonide. E-2-(2,6-Dicyanophenyl)-N,N-dimethylethenamine was formed by condensation of 2,6-dicyanotoluene with dimethylformamide dimethyl acetal (DMFDMA); cyclisation under acidic conditions afforded 5-cyanoisoquinolin-1-one. Heck coupling of 5-iodoisoquinolin-1-one with propenoic acid formed E-3-(1-oxoisoquinolin-5-yl)propenoic acid. 3-Oxiranylbenzamide, 5-bromoisoquinolin-1-one and 5-iodoisoquinolin-1-one were among the most potent inhibitors of PARP activity in a preliminary screen in vitro. Copyright (C) 1998 Elsevier Science Ltd.